These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24881816)

  • 1. Predicting natural product value, an exploration of anti-TB drug space.
    Dashti Y; Grkovic T; Quinn RJ
    Nat Prod Rep; 2014 Aug; 31(8):990-8. PubMed ID: 24881816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives on natural products in TB drug research.
    Pauli GF; Case RJ; Inui T; Wang Y; Cho S; Fischer NH; Franzblau SG
    Life Sci; 2005 Dec; 78(5):485-94. PubMed ID: 16243360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model to predict anti-tuberculosis activity: value proposition for marine microorganisms.
    Liu M; Grkovic T; Zhang L; Liu X; Quinn RJ
    J Antibiot (Tokyo); 2016 Aug; 69(8):594-9. PubMed ID: 27406906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitubercular Marine Natural Products.
    Wang L; Wang J; Liu J; Liu Y
    Curr Med Chem; 2018; 25(20):2304-2328. PubMed ID: 28088903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purity-activity relationships of natural products: the case of anti-TB active ursolic acid.
    Jaki BU; Franzblau SG; Chadwick LR; Lankin DC; Zhang F; Wang Y; Pauli GF
    J Nat Prod; 2008 Oct; 71(10):1742-8. PubMed ID: 18798682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico comparison of antimycobacterial natural products with known antituberculosis drugs.
    Espinoza-Moraga M; Njuguna NM; Mugumbate G; Caballero J; Chibale K
    J Chem Inf Model; 2013 Mar; 53(3):649-60. PubMed ID: 23410241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents.
    Farah SI; Abdelrahman AA; North EJ; Chauhan H
    Assay Drug Dev Technol; 2016; 14(1):29-38. PubMed ID: 26565779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationship studies of tryptanthrins as antitubercular agents.
    Hwang JM; Oh T; Kaneko T; Upton AM; Franzblau SG; Ma Z; Cho SN; Kim P
    J Nat Prod; 2013 Mar; 76(3):354-67. PubMed ID: 23360475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
    Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
    Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, antimycobacterial evaluation and pharmacophore modeling of analogues of the natural product formononetin.
    Mutai P; Pavadai E; Wiid I; Ngwane A; Baker B; Chibale K
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2510-3. PubMed ID: 25977095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural products as leads for tuberculosis drug development.
    Salomon CE; Schmidt LE
    Curr Top Med Chem; 2012; 12(7):735-65. PubMed ID: 22283816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural antimicrobial peptides against Mycobacterium tuberculosis.
    Abedinzadeh M; Gaeini M; Sardari S
    J Antimicrob Chemother; 2015 May; 70(5):1285-9. PubMed ID: 25681127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative protein modeling of methionine S-adenosyltransferase (MAT) enzyme from Mycobacterium tuberculosis: a potential target for antituberculosis drug discovery.
    Khedkar SA; Malde AK; Coutinho EC
    J Mol Graph Model; 2005 Jan; 23(4):355-66. PubMed ID: 15670956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of Anti-Tuberculosis Activity Behaviour of Natural Kaurane and Trachylobane Diterpenes Compared with Structural Properties Obtained by Theoretical Calculations.
    Soares ACF; Cabral MMW; Martins CHG; Ferreira AE; Bergamo PAS; Omosa LK; Midiwo JO; Parreira RLT; Heleno VCG
    Nat Prod Commun; 2017 May; 12(5):763-769. PubMed ID: 30496662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current perspectives in drug discovery against tuberculosis from natural products.
    Nguta JM; Appiah-Opong R; Nyarko AK; Yeboah-Manu D; Addo PG
    Int J Mycobacteriol; 2015 Sep; 4(3):165-83. PubMed ID: 27649863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensively drug-resistant (XDR) tuberculosis: an old and new threat.
    Fattorini L; Migliori GB; Cassone A
    Ann Ist Super Sanita; 2007; 43(4):317-9. PubMed ID: 18209265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.